Catalent acquires US Commercial Cell Therapy Facility

Establishing US-based campus to support late-stage and commercial manufacturing for autologous and allogeneic cell therapies

Catalent Invests $350 Million at Bloomington, Indiana Site

Expanding Biomanufacturing and Fill/Finish Capabilities

Developing Biologic Drugs is Science.

Accelerating Advanced Treatments & Vaccines is Art.

Catalent acquires US Commercial Cell Therapy Facility

Establishing US-based campus to support late-stage and commercial manufacturing for autologous and allogeneic cell therapies

Catalent Invests $350 Million at Bloomington, Indiana Site

Expanding Biomanufacturing and Fill/Finish Capabilities

Developing Biologic Drugs is Science.

Accelerating Advanced Treatments & Vaccines is Art.